Bio-Rad Laboratories (BIO) Projected to Post Quarterly Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) is anticipated to post its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Bio-Rad Laboratories to post earnings of $2.57 per share and revenue of $694.6380 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Bio-Rad Laboratories Stock Up 2.5%

BIO stock opened at $306.53 on Thursday. The company has a market cap of $8.27 billion, a price-to-earnings ratio of -12.61 and a beta of 1.18. The company has a fifty day moving average price of $309.69 and a 200 day moving average price of $299.35. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.44 and a quick ratio of 3.94. Bio-Rad Laboratories has a 12 month low of $211.43 and a 12 month high of $351.02.

Analyst Ratings Changes

Several brokerages have recently weighed in on BIO. Citigroup increased their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company upped their price target on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $358.50.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of large investors have recently made changes to their positions in BIO. Geneos Wealth Management Inc. grew its position in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares during the period. Quarry LP boosted its stake in shares of Bio-Rad Laboratories by 131.5% during the 3rd quarter. Quarry LP now owns 287 shares of the medical research company’s stock worth $80,000 after acquiring an additional 163 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Bio-Rad Laboratories by 241.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 331 shares of the medical research company’s stock worth $93,000 after acquiring an additional 234 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $211,000. Finally, WFA of San Diego LLC purchased a new position in Bio-Rad Laboratories in the 2nd quarter valued at approximately $222,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.